The latest earnings announcement Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) released in December 2018 indicated company earnings became less negative compared to the previous year’s level – great news for investors Below, I’ve laid out key numbers on how market analysts perceive Syndax Pharmaceuticals’s earnings growth trajectory over the next few years and whether the future looks brighter. Note that I will be looking at net income excluding extraordinary items to get a better understanding of the underlying drivers of earnings.
Market analysts’ consensus outlook for the coming year seems buoyant, with earnings becoming less negative, arriving at -US$60.6m in 2020.
Although it is helpful to be aware of the rate of growth year by year relative to today’s value, it may be more insightful determining the rate at which the company is moving every year, on average. The benefit of this technique is that we can get a better picture of the direction of Syndax Pharmaceuticals’s earnings trajectory over the long run, irrespective of near term fluctuations, fluctuate up and down. To calculate this rate, I’ve appended a line of best fit through analyst consensus of forecasted earnings. The slope of this line is the rate of earnings growth, which in this case is 25%. This means, we can expect Syndax Pharmaceuticals will grow its earnings by 25% every year for the next few years.
For Syndax Pharmaceuticals, there are three key aspects you should look at:
- Financial Health: Does it have a healthy balance sheet? Take a look at our free balance sheet analysis with six simple checks on key factors like leverage and risk.
- Future Earnings: How does SNDX’s growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High-Growth Alternatives: Are there other high-growth stocks you could be holding instead of SNDX? Explore our interactive list of stocks with large growth potential to get an idea of what else is out there you may be missing!
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at firstname.lastname@example.org. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.